In this study, two original bioanalytical methods for quantification of eicosanoids biosynthesised from arachidonic acid (AA) via different metabolic pathways were developed and validated using UPLC-MS/MS technique. The methods allowed to assess the eicosanoid profile in selected animal models of endothelial dysfunction and its changes upon pharmacological modulation of vascular function.In NO-deficient mice, the biosynthesis of eicosanoids formed by cyclooxygenase (COX) was elevated. MNA treatment improved the vessel function by activation of COX-independent mechanisms.In murine model of hypertension, angiotensin II infusion increased the biosynthesis of CYP450- derived 20-HETE. The inhibition of thrombin activity by dabigatran improved the function of endothelium by sustaining the NO bioavailability and reducing the 20-HETE production.The development of 4T1 breast cancer was associated with the elevated biosynthesis of eicosanoids formed by COX and lipoxygenase (LOX) and with the reduced production of CYP450-derived AA metabolites. The inhibition of NO synthase increased the biosynthesis of epoxyeicosatrienoic acids (EET) and 20-HETE, which probably supported the disease progression under NO-deficiency.The obtained results show the heterogeneity of eicosanoid profile in investigated murine models of endothelial dysfunction and the pharmacological modulation of vascular functi ; on indicates which AA metabolic pathways could be an effective target in the treatment of hypertension and breast cancer.
21 cze 2023
7 paź 2020
8
0
http://dl.cm-uj.krakow.pl:8080/publication/4382
Nazwa wydania | Data |
---|---|
ZB-131048 | 21 cze 2023 |
Kij, Agnieszka
Paciorek, Anna
Basta, Paweł
Streb, Joanna
Glajcar, Anna
Hubalewska-Mazgaj, Magdalena